Schrader B J, Inbar S, Kaufmann L, Vestal R E, Rich S
Department of Pharmacy Practice, University of Illinois, Chicago.
J Am Coll Cardiol. 1992 Apr;19(5):1060-4. doi: 10.1016/0735-1097(92)90295-x.
The hemodynamic effects of intravenously administered adenosine, a potent vasodilator, were examined in 15 patients with pulmonary hypertension. All patients were given adenosine, 50 micrograms/kg per min, increased by 50 micrograms/kg per min at 2 min intervals to a maximum of 500 micrograms/kg per min or until the development of untoward side effects. The patients were then given oral nifedipine, 20 mg every hour, until a greater than or equal to 20% decrease in pulmonary vascular resistance or systemic hypotension occurred. The administration of maximal doses of adenosine, 256 +/- 46 micrograms/kg per min, produced a 2.4% reduction in pulmonary artery pressure (p = NS), a 37% decrease in pulmonary vascular resistance (p less than 0.001) and a 57% increase in cardiac index (p less than 0.001). The administration of maximally effective doses of nifedipine (91 +/- 36 mg) produced a 15% reduction in the mean pulmonary artery pressure (p less than 0.05), a 24% decrease in pulmonary vascular resistance (p less than 0.01) and an 8% increase in cardiac index (p = NS). There was a significant correlation (r = 0.714, p = 0.01) between the reduction in pulmonary vascular resistance that resulted from adenosine administration and that achieved with the administration of nifedipine. Six patients had substantial reductions in pulmonary vascular resistance with adenosine but not with nifedipine. Thus, adenosine is an effective vasodilator in patients with pulmonary hypertension and can be used for safe and rapid assessment of vasodilator reserve in these patients.(ABSTRACT TRUNCATED AT 250 WORDS)
对15例肺动脉高压患者研究了静脉注射强效血管扩张剂腺苷的血流动力学效应。所有患者均给予腺苷,起始剂量为50微克/千克每分钟,每2分钟增加50微克/千克每分钟,最大剂量至500微克/千克每分钟或直至出现不良反应。然后患者每小时口服硝苯地平20毫克,直至肺血管阻力降低大于或等于20%或出现系统性低血压。静脉注射最大剂量腺苷(256±46微克/千克每分钟)可使肺动脉压降低2.4%(p=无显著性差异),肺血管阻力降低37%(p<0.001),心脏指数增加57%(p<0.001)。口服最大有效剂量硝苯地平(91±36毫克)可使平均肺动脉压降低15%(p<0.05),肺血管阻力降低24%(p<0.01),心脏指数增加8%(p=无显著性差异)。腺苷给药后肺血管阻力的降低与硝苯地平给药后肺血管阻力的降低之间存在显著相关性(r=0.714,p=0.01)。6例患者使用腺苷后肺血管阻力显著降低,但使用硝苯地平后未降低。因此,腺苷对肺动脉高压患者是一种有效的血管扩张剂,可用于安全、快速评估这些患者的血管扩张储备。(摘要截短至250字)